Why did this $1.4 billion ASX 200 healthcare stock just dive 9%?

The market didn't like what this stock had to say this morning…

| More on:
Shot of a senior scientist looking stressed out while working in a lab.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

After a strong start to the morning's trade, things don't look so upbeat for the S&P/ASX 200 Index (ASX: XJO) this afternoon. At the time of writing, the ASX 200 has given up most of its early lead today, and is sitting pretty much flat at 8,226 points. But let's talk about one ASX 200 healthcare stock that is plunging in value.

That ASX 200 healthcare stock is none other than Neuren Pharmaceuticals Ltd (ASX: NEU).

Yesterday, Neuren shares closed at a flat $12 each. This morning, those same shares opened at $12.03 but quickly started dropping. At the time of writing, the ASX 200 healthcare stock has lost a horrid 8.83% and is down to just $10.94 a share. That's after going as low as $10.90 this afternoon.

So what on earth is going on here that has seen Neuren lose close to 10% of its value in just a single trading day?

Well, it appears that this steep sell-off is a consequence of an ASX announcement Neuren made to investors this morning just before market open.

Neuren shares plunge amid big Europe news

This announcement revealed that Neuren's partner, Acadia Pharmaceuticals, has submitted a marketing authorization application to the European Medicines Agency for its trofinetide treatment. Trofinetide is a therapeutic treatment for Rett syndrome in adults and pediatric patients two years and older.

Acadia Pharmaceuticals reportedly expects approval for trofinetide to occur in the first quarter of 2026. If it does indeed gain approval from the relevant agencies, it will be the "first and only approved therapy for Rett syndrome in the European Union".

Trofinetide is already an approved treatment for Rett syndrome in the United States and Canada under the 'Daybue' trademark.

If approved, Acadia will sell trofinetide in Europe under license from Neuren. Upon the first commercial sale of the treatment in Europe, Neuren is contracted to receive a US$35 million payment from Acadia. That's in addition to ongoing royalty payments.

Why has this ASX 200 healthcare stock taken a dive?

It's not entirely clear why investors have reacted so poorly to this news out of Neuren today. The rollout of trofinetide in Europe has been anticipated for some time.

Perhaps investors were expecting a quicker European rollout or an announcement regarding other planned rollouts in Japan and other countries.

Regardless, it's a rough day for this ASX 200 healthcare stock. It's also some fresh salt in the wounds of Neuren's investors.

After today's share price plunge, this ASX 200 healthcare stock is down a painful 53.6% over the past 12 months. Investors will no doubt hope for a turnaround over the rest of 2025.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 9 January 2025

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A financial expert or broker looks worried as he checks out a graph showing market volatility.
Healthcare Shares

Mesoblast shares dip then flip on $800,000 insider buy

The Mesoblast share price is resettling after a near-70% spike in December.

Read more »

Young investor watching share chart in anticipation
Healthcare Shares

Here's the earnings forecast out to 2029 for CSL shares

This biotech giant could see significant profit growth in the coming years.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

With a projected 7% dividend yield, is the Medibank share price a buy?

Investors may receive very healthy dividends from this stock.

Read more »

Healthcare Shares

Guess which ASX 200 stock is jumping to record high on big European news

What is getting investor excited on Friday? Let's see what is happening.

Read more »

Man with rocket wings which have flames coming out of them.
Healthcare Shares

Goldman Sachs tips ResMed shares to rocket 30% to a record high

The broker is feeling very bullish about the sleep disorder treatment company.

Read more »

A bland looking man in a brown suit opens his jacket to reveal a red and gold superhero dollar symbol on his chest.
Healthcare Shares

Why CSL shares could be dirt cheap in 2025

Goldman Sachs sees a lot of value in this blue chip stock.

Read more »

The last piece of the jigsaw being fitted, indicating good news for a share price on merger or acquisition
Healthcare Shares

What will happen to the Sigma share price after the Chemist Warehouse merger?

Morgan Stanley analysts explain the default factor that will support the Sigma share price after the merger.

Read more »

Shot of a young scientist looking stressed while conducting medical research in a laboratory.
Broker Notes

Why this top fundie has a 'loss of confidence' in CSL shares

CSL has a lot of broker support right now but Firetrail has an opposing view on the ASX 200 healthcare…

Read more »